measuring whole blood thrombin generation in patients with multiple myeloma
Published 2 years ago • 98 plays • Length 3:42Download video MP4
Download video MP3
Similar videos
-
2:05
using mrd negativity to measure depth of response & to discontinue treatment in multiple myeloma
-
3:06
phase i study of hpn217 in patients with r/r multiple myeloma
-
2:22
whole blood thrombin generation in trauma
-
1:37
challenges in treating patients with triple-class refractory multiple myeloma
-
0:58
minimumm-seq: a novel, minimally invasive approach to characterize myeloma pathology
-
3:28
viome instructions for blood collection
-
2:17
mrd: a promising biomarker in multiple myeloma
-
16:10
hematology lecture 1 blood transfusion reaction part 2/3
-
3:04
monumental-1 update: talquetamab in r/r multiple myeloma
-
5:18
response monitoring in multiple myeloma
-
0:46
2-year follow-up of majestec-1: teclistamab in r/r multiple myeloma
-
0:59
defining the origins of multiple myeloma
-
2:01
ctcs as a biomarker of tumor burden in multiple myeloma
-
2:49
trimm-2 update: talquetamab daratumumab in r/r multiple myeloma
-
2:12
results from phase i study of alnuctamab administered intravenously & subcutaneously in r/r myeloma
-
1:11
measuring treatment response rates in multiple myeloma
-
5:49
magnetismm-3 extended follow up results: elranatamab monotherapy in r/r multiple myeloma
-
5:54
redirectt-1 results: teclistamab talquetamab in r/r multiple myeloma
-
1:56
treatment selection & sequencing in patients with relapsed, intolerant, or refractory myeloma
-
1:50
real-world outcomes of teclistamab treatment in r/r multiple myeloma
-
1:59
methods used to assess mrd status in multiple myeloma
-
4:45
a first-in-human trial of regn5458 in r/r myeloma: updated phase i data